Acurx Pharmaceuticals, Inc. earnings releases ACXP

Annual Quarterly

Acurx Pharmaceuticals, Inc. last reported quarterly results on May 13, 2025, for Q1 FY2025 (the quarter ended Mar 31, 2025): diluted EPS of -$2.15. It usually reports 40–45 days after a quarter ends.

Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 40–45 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.

Released	Quarter	Revenue	Net income	Diluted EPS
May 13, 2025 43 days after quarter end	Q1 FY2025 ended Mar 31, 2025	—	-2 +50.9%	-2.15 -667.9%
Nov 13, 2024 44 days after quarter end	Q3 FY2024 ended Sep 30, 2024	—	-3 +9.4%	-3.45 -1337.5%
Aug 9, 2024 40 days after quarter end	— ended Jun 30, 2024	—	—	—
May 15, 2024 45 days after quarter end	— ended Mar 31, 2024	—	—	—
Nov 14, 2023 45 days after quarter end	— ended Sep 30, 2023	—	—	—
Aug 14, 2023 45 days after quarter end	— ended Jun 30, 2023	—	—	—
Mar 16, 2023 75 days after quarter end	— ended Dec 31, 2022	—	—	—
Nov 14, 2022 45 days after quarter end	— ended Sep 30, 2022	—	—	—

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: ACXP (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Staten Island, NY
SEC filer status: , Emerging growth company
SEC CIK: 1736243
Former names: Acurx Pharmaceuticals, LLC (until Jun 23, 2021)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.